The vagus nerve is the primary parasympathetic highway to the thoracic and abdominal organs — but only about 20 percent of its fibres carry the efferent (brain-to-body) signals that most people associate with “parasympathetic.” The remaining 80 percent are afferent, carrying sensory information from the organs back to the brainstem. This asymmetry matters because the vagus nerve’s clinical significance lies in both directions: the efferent fibres that slow the heart, contract the gut, and suppress inflammation, and the afferent fibres that inform the brain about the state of every organ they innervate. Understanding where parasympathetic efferent fibres go, what they do at each target, and what happens when they fail is the foundation for understanding vagal tone, vagus nerve stimulation, and the growing field of bioelectronic medicine.
Cardiac Efferents: The Vagal Brake
The heart receives vagal efferent fibres via the superior and inferior cardiac branches, which synapse in the cardiac ganglia embedded in the epicardial fat pads. Postganglionic fibres release acetylcholine onto muscarinic M2 receptors on the sinoatrial (SA) node, atrioventricular (AV) node, and atrial myocardium. The effect is immediate: acetylcholine opens potassium channels (IKACh), hyperpolarising the pacemaker cells and slowing the rate of spontaneous depolarisation. Heart rate drops within one to two beats of vagal activation — far faster than the sympathetic system can accelerate it.
This speed is clinically important. The “vagal brake” is the mechanism by which the heart decelerates rapidly in response to changing demands — standing up, finishing a sprint, or transitioning from stress to rest. Heart rate variability (HRV), specifically the beat-to-beat variation timed to respiration (respiratory sinus arrhythmia), is a direct readout of vagal efferent traffic to the SA node. RMSSD — the root mean square of successive differences between heartbeats — is the metric most specific to cardiac vagal output.
When cardiac vagal efferent function is impaired, the consequences are measurable and clinically significant. The VET Registry (2024, JAHA) followed 501 veterans for 12 years and found that each one-standard-deviation increase in deceleration capacity — a measure of vagal cardiac control — was associated with a 27 percent lower hazard of all-cause mortality. A separate 2,501-participant study linked SDNN below 70 milliseconds after myocardial infarction to a fourfold increase in three-year cardiac mortality. The heart’s dependence on tonic vagal restraint is so fundamental that losing it — through diabetic neuropathy, surgical injury, or chronic stress — shifts the entire cardiovascular risk profile.
Pulmonary Efferents: Airway Calibre and Mucus
Vagal parasympathetic fibres reach the lungs via the pulmonary plexus, synapsing in parasympathetic ganglia within the airway walls. Postganglionic fibres release acetylcholine onto M3 receptors on bronchial smooth muscle, causing contraction (bronchoconstriction), and onto submucosal glands, stimulating mucus secretion. This is not a design flaw — baseline vagal bronchomotor tone maintains airway calibre at an optimal diameter for gas exchange and mucociliary clearance.
In asthma, the parasympathetic reflex arc becomes pathologically amplified. Irritant receptors in the airway epithelium activate vagal afferents, which trigger a reflex increase in vagal efferent output, producing excessive bronchoconstriction and mucus hypersecretion. Anticholinergic bronchodilators (ipratropium, tiotropium) work by blocking the muscarinic receptors at the end of this pathway — they do not suppress vagal firing but block its effect at the target organ. Understanding this distinction is important because vagal efferent traffic to the lungs also carries anti-inflammatory signals through the same cholinergic pathway described below for the spleen, and globally suppressing vagal function would sacrifice the anti-inflammatory benefit along with the bronchoconstrictor reflex.
Your local vagus nerve experts
Find a vagus nerve practitioner near you
Our directory lists 2,685 practitioners across the US, from polyvagal-informed therapists to HRV biofeedback clinics.
Or browse by approach
- Polyvagal-informed therapy
- Somatic therapy
- HRV biofeedback
- Craniosacral therapy
- Breathwork
- Insomnia therapy (CBT-I)
The directory covers the United States for now. Listings come from practitioners’ own websites and are not endorsements or medical advice. Browse the full directory.
Gastrointestinal Efferents: Motility, Secretion, and the Enteric Brain
The vagus nerve provides parasympathetic innervation to the entire gastrointestinal tract from the oesophagus to the proximal two-thirds of the transverse colon. (The distal colon and rectum receive parasympathetic supply from the pelvic splanchnic nerves, S2–S4 — not the vagus.) Vagal efferents synapse on neurons in the myenteric (Auerbach’s) and submucosal (Meissner’s) plexuses, which constitute the enteric nervous system — often called the “second brain” because it contains approximately 500 million neurons capable of operating semi-independently.
The vagal efferent signal to the gut does not micromanage every contraction. Instead, it modulates the enteric nervous system’s activity: increasing the frequency and force of peristaltic waves, stimulating gastric acid and enzyme secretion, relaxing the pyloric sphincter to allow gastric emptying, and promoting bile release from the gallbladder. Acetylcholine from vagal preganglionic fibres activates nicotinic receptors on enteric neurons, which then use their own neurotransmitter cascades to execute the final motor and secretory programmes.
When vagal efferent input to the gut is lost — through surgical vagotomy, diabetic autonomic neuropathy, or direct injury — the result is gastroparesis: delayed gastric emptying causing nausea, early satiety, bloating, and vomiting of undigested food hours after eating. A 2024 Frontiers in Neurology editorial reframed gastroparesis as a combined neural, muscular, and biochemical disturbance rather than a purely vagal problem, noting that loss of interstitial cells of Cajal (the gut’s pacemaker cells) frequently accompanies vagal neuropathy, compounding the motility deficit. This is why gastroparesis is often refractory to treatment: restoring vagal input alone may not be sufficient if the pacemaker cell network has degenerated.
A January 2025 study in iScience (Jameson et al., UCLA) provided causal evidence that gut microbiota communicate with the brain through vagal afferents by producing short-chain fatty acids and bile acids that directly modulate vagal nerve firing. This confirms the vagus as the primary neural route in the gut-brain axis — but the signalling is bidirectional. Efferent vagal input shapes the gut environment that determines which microbial metabolites are produced, creating a feedback loop between brain, nerve, and microbiome.
Hepatic and Pancreatic Branches: Metabolic Regulation
The hepatic branch of the vagus nerve innervates the liver and contributes to the regulation of glucose metabolism. Vagal efferent signals promote hepatic glycogen synthesis (storing glucose) and suppress gluconeogenesis (making new glucose). Animal studies have shown that hepatic vagotomy impairs the liver’s ability to respond to insulin signalling, suggesting that vagal parasympathetic input is part of the mechanism by which the brain regulates blood sugar levels.
Vagal efferent fibres also reach the pancreatic islets, where they stimulate insulin secretion from beta cells through muscarinic M3 receptors. This “cephalic phase” insulin release — triggered by the sight, smell, or anticipation of food before any glucose enters the blood — is entirely vagally mediated. The clinical relevance is apparent in truncal vagotomy patients, who show impaired early-phase insulin secretion and altered glucose tolerance, contributing to the metabolic consequences of vagal injury that extend well beyond the digestive symptoms most clinicians monitor.
The Spleen: The Cholinergic Anti-Inflammatory Pathway
The most transformative discovery in vagal physiology over the past two decades is the cholinergic anti-inflammatory pathway, identified by Kevin Tracey and colleagues at the Feinstein Institutes. The mechanism: vagal efferent fibres activate the splenic nerve (a sympathetic nerve, not a vagal branch — the relay is indirect), which releases norepinephrine in the spleen. Norepinephrine activates a subset of T cells that produce acetylcholine, which then binds to alpha-7 nicotinic acetylcholine receptors (alpha7nAChR) on macrophages, suppressing their production of pro-inflammatory cytokines — tumour necrosis factor (TNF), interleukin-1 (IL-1), and interleukin-6 (IL-6).
This pathway moved from animal models to clinical reality in July 2025, when the FDA approved SetPoint Medical’s implantable vagus nerve stimulator for rheumatoid arthritis — the first VNS device approved for an autoimmune condition. In the pivotal RESET-RA trial of 242 patients who had failed biologic or targeted synthetic DMARDs, a 60-second daily stimulation produced ACR20 response rates of 35.2 percent with serious adverse events below 2 percent. The anti-inflammatory effect occurs without immunosuppression — unlike biologic DMARDs, VNS does not increase infection risk — because it modulates rather than blocks the immune response.
The broader implication is that every condition driven by chronic inflammation — from inflammatory bowel disease to atherosclerosis to neurodegeneration — has a vagal component. When tonic vagal efferent activity is low (measurable as reduced HRV), the inflammatory brake is weaker, and baseline cytokine levels drift upward. This may explain part of the epidemiological link between low vagal tone and elevated cardiovascular, metabolic, and neurodegenerative risk.
Laryngeal and Pharyngeal Branches: Voice and Airway Protection
The recurrent laryngeal nerve (RLN) and the superior laryngeal nerve (SLN) — both branches of the vagus — control the muscles of the larynx. The RLN innervates all intrinsic laryngeal muscles except the cricothyroid, controlling vocal fold adduction (closing for phonation and airway protection) and abduction (opening for breathing). The SLN’s external branch innervates the cricothyroid, which tenses the vocal folds for pitch control, while its internal branch provides the sensory trigger for the cough and swallow reflexes.
Injury to the RLN — most commonly during thyroid, parathyroid, or anterior cervical spine surgery — produces hoarseness if unilateral and potentially life-threatening airway obstruction if bilateral. A 2026 retrospective study of 488 patients (Kweh et al., AME Surgical Journal) found a 7.6 percent rate of symptomatic vocal cord palsy after anterior cervical surgery, with operations at C7/T1 carrying the highest risk (21 percent versus 5.8 percent at other levels). Intraoperative nerve monitoring (IONM) has reduced RLN injury rates from 12–14 percent to approximately 2.4 percent in thyroid surgery, according to a 2024 Frontiers in Endocrinology analysis.
Measuring Parasympathetic Efferent Function
Because vagal parasympathetic effects are distributed across so many organs, no single test captures total vagal efferent function. Clinical autonomic testing uses a battery approach: the heart rate deep breathing test (HRDB) measures cardiac vagal output by quantifying the heart rate range during slow breathing; the Valsalva ratio tests baroreflex-mediated vagal recovery; and gastric emptying studies assess vagal GI function. Wearable HRV monitors provide continuous longitudinal data on cardiac vagal tone, with overnight RMSSD being the least affected by daily variables and the most useful for tracking trends.
High-resolution ultrasound of the vagus nerve at the cervical level — measuring cross-sectional area (CSA) — has emerged as a structural complement to these functional tests. Normal values are approximately 1.2 mm squared on the left and 1.5 mm squared on the right, with the right vagus consistently larger across studies. Reduced CSA has been correlated with vagal neuropathy in Parkinson’s disease and diabetes, though the sensitivity is not yet sufficient for individual diagnostic use.
The Feinstein Institutes’ REVA project, published in July 2026, produced the first comprehensive three-dimensional atlas of the human vagus nerve using microCT, immunohistochemistry, and ultrasound across 30 donors and 60 nerves. Among its findings: organ-specific fascicles are spatially organised within the nerve trunk, becoming distinct approximately 1–1.5 centimetres before the branch point. This mapping is critical for the next generation of selective VNS devices, which aim to stimulate only the fascicles relevant to a target organ — boosting anti-inflammatory efferents to the spleen without affecting cardiac efferents, for example.
The vagus nerve’s parasympathetic reach — from heartbeat to gut motility to inflammatory control — makes it the single most important autonomic pathway in the body. Understanding what each branch does, and what fails when it stops working, is the foundation for every vagal health strategy. My Vagus Nerve & Me maps the complete parasympathetic pathway, explains how vagal tone is measured, and connects the science to practical interventions backed by evidence. Get My Vagus Nerve & Me eBook and understand the nerve that runs your rest-and-repair system.




